Compare Rivian Automotive, Inc. (RIVN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs TG Therapeutics Inc — how do they compare? Rivian Automotive, Inc. trades at $17.18 (market cap $25.71B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Rivian Automotive, Inc. is far larger — about 3.1× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| RIVN | TGTX | |
|---|---|---|
Market Cap | $25.71B | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $59.06 |
52-Week Low | $11.64 | $26.39 |
Enterprise Value | $27.45B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $17.76, up 1.75% on the day, with a neutral technical outlook and bullish moving averages. The company continues to post significant losses, with a net income margin of -63.62% in 2025, though revenue grew to $5.39 billion. Recent news highlights focus on the upcoming R2 vehicle launch and a challenging EV market environment.
Rivian's investment case hinges on successful execution of the R2 launch and path to profitability, but faces substantial risks from cash burn, competition, and macroeconomic pressures. Analyst consensus is a Buy with a $19.22 price target, suggesting moderate upside potential from current levels if operational improvements materialize.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
